Hester BiosQ3 FY24

Hester Bios Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,324.6P/E: 33.7Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Poultry division is on a recovery path with a positive upswing in vaccine and health product sales expected to continue into FY25.
  • Management anticipates double-digit growth in the domestic poultry vaccine division but refrains from giving specific percentage guidance publicly.
  • The new CuRx LA product is expected to neutralize previous sales losses within one year, contributing to growth.
  • Expansion efforts in African markets are ongoing, with hopes for improved sales once product registrations complete and local teams are hired.
  • Animal Health division shows a 17% growth in health product sales excluding discontinued brands and is launching line extensions expected to mitigate past sales losses.
  • Development of new vaccines and introduction of pet product lines indicate plans for diversification and long-term growth.
  • Overall emphasis on stabilizing and growing existing segments, with readiness to invest selectively in infrastructure like pilot R&D plants if needed.

See what Hester Bios management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no current plan, desire, or thought of selling any existing facilities to raise funds.
  • The company is managing existing expenditures for ongoing projects without additional major capital expenditure except potentially for creating a pilot R&D plant; timing and decision on this are yet to be finalized.
  • No mention of new fundraising through debt or equity was made in the call.
  • The management is focusing on optimizing current operations and infrastructure to support growth with existing resources.
  • The balance sheet is noted to be leveraged, but no explicit plan for fresh equity or debt issuance is indicated.

See what Hester Bios management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Current CAPEX is limited to necessary expenditures to rejig existing facilities to support committed projects and pipeline vaccines, most of which do not require additional capital expenditure.
  • A significant potential CAPEX involves creating a pilot R&D plant, with timing and decision still under consideration.
  • There is no plan to sell any existing antigen-generating or vaccine manufacturing facilities; repurposing of the human vaccine facility (BSL-3 lab) is underway pending government concurrence.
  • The company is managing other investments within already incurred expenditures and focusing on efficiency.
  • Recruitment investments are planned mainly for expanding sales infrastructure in African markets once product registrations are completed, but these are operational expenses rather than CAPEX.

Track Hester Bios — get its next earnings analysis in your feed

How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHester Bios
Rev 3Mar 3

How does Hester Bios rank in Pharmaceuticals & Biotechnology?

Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →